Risk of Second Primary Malignancies in Colon Cancer Patients Treated With Colectomy

doi:10.3389/fonc.2020.01154

	Risk of Second Primary Malignancies in Colon Cancer Patients Treated With Colectomy
	Zhang, Bo 1,2; Guo, Kaibo 3; Zheng, Xueer 3; Sun, Leitao 3,4; Shen, Minhe 4; Ruan, Shanming 3,4
刊名	FRONTIERS IN ONCOLOGY
	2020-07-16
卷号	10
关键词	second primary malignancy colon cancer prostate cancer competing risk model nomogram
ISSN号	2234-943X
DOI	10.3389/fonc.2020.01154
通讯作者	Ruan, Shanming(shanmingruan@zcmu.edu.cn)
英文摘要	Background:Second primary malignancy (SPM) attracts a growing attention. However, the clinical features of colon cancer (CC) survivors with SPMs are not clear and could help guide clinicians to develop a better surveillance strategy. Methods:We reviewed 56,930 CC survivors treated with colectomy from the Surveillance, Epidemiology, and End Results (SEER) database during 1998-2011. Competing risk models and nomograms were conducted for predicting the risk of occurring SPMs. The clinical utility of the models was measured by decision curve analysis (DCA) using net benefit approaches. Results:Five thousand thirteen (17.1%) of male patients developed SPMs and sites of SPMs included prostate (32.2%), lung and bronchus (11.6%), urinary bladder and kidney (10.8%), colon (10.0%), and melanoma of the skin (3.9%), while 3,592 (13.0%) of female patients occurred SPMs and sites of SPMs involved breast (25.8%), lung and bronchus (13.6%), colon (11.6%), uterus (8.2%), urinary bladder, and kidney (5.6%). Survivors with a second carcinoma of lung and bronchus showed the worst prognosis. Older age increased the risk of SPMs in both male (Subdistribution hazard ratio =2.85 [95% confidence interval = 2.53-3.21]) and female (1.80 [1.59-2.04]) survivors, especially for the risk of a second prostate carcinoma in male (5.33 [4.03-7.03]). Compared with white race, black male survivors remained at higher risk to develop the second prostate carcinoma (1.98 [1.74-2.26]). Competing-risk nomograms for CC survivors were established to help clinicians predict the probabilities of overall SPMs and prostate carcinoma. Validation of nomograms showed good discrimination and accuracy, and DCAs revealed the clinical effectiveness. Conclusions:We profiled the clinical characteristics of a large population-based cohort of CC survivors with SPMs. These features may improve future follow-up management, especially for the surveillance of second prostate cancer in men and second breast cancer in women.
资助项目	Natural Science Foundation of Zhejiang Province[LQ20H290001] ; National Natural Science Foundation of China[81573902] ; China Postdoctoral Science Foundation[2017M612040] ; China Postdoctoral Science Foundation[2018T110610] ; Program for the Cultivation of Youth talents in China Association of Chinese Medicine[QNRC2-C08] ; Zhejiang Provincial Program for the Cultivation of the Young and Middle-Aged Academic Leaders in Colleges and Universities[2017-248] ; Zhejiang Provincial Project for the key discipline of Traditional Chinese Medicine[2017-XK-A09]
WOS关键词	SURVIVORS ; AGE
WOS研究方向	Oncology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000556740700001
资助机构	Natural Science Foundation of Zhejiang Province ; National Natural Science Foundation of China ; China Postdoctoral Science Foundation ; Program for the Cultivation of Youth talents in China Association of Chinese Medicine ; Zhejiang Provincial Program for the Cultivation of the Young and Middle-Aged Academic Leaders in Colleges and Universities ; Zhejiang Provincial Project for the key discipline of Traditional Chinese Medicine
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/44778]
专题	中国科学院合肥物质科学研究院
通讯作者	Ruan, Shanming
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China 3.Zhejiang Chinese Med Univ, Clin Med Coll 1, Hangzhou, Peoples R China 4.Zhejiang Chinese Med Univ, Dept Med Oncol, Affiliated Hosp 1, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Zhang, Bo,Guo, Kaibo,Zheng, Xueer,et al. Risk of Second Primary Malignancies in Colon Cancer Patients Treated With Colectomy[J]. FRONTIERS IN ONCOLOGY,2020,10.
APA	Zhang, Bo,Guo, Kaibo,Zheng, Xueer,Sun, Leitao,Shen, Minhe,&Ruan, Shanming.(2020).Risk of Second Primary Malignancies in Colon Cancer Patients Treated With Colectomy.FRONTIERS IN ONCOLOGY,10.
MLA	Zhang, Bo,et al."Risk of Second Primary Malignancies in Colon Cancer Patients Treated With Colectomy".FRONTIERS IN ONCOLOGY 10(2020).